<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31258670</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1792-0981</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Experimental and therapeutic medicine</Title><ISOAbbreviation>Exp Ther Med</ISOAbbreviation></Journal><ArticleTitle>Enterovirus type 71-immunized chicken egg yolk immunoglobulin has cross antiviral activity against coxsackievirus A16 <i>in vitro</i>.</ArticleTitle><Pagination><StartPage>332</StartPage><EndPage>341</EndPage><MedlinePgn>332-341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/etm.2019.7529</ELocationID><Abstract><AbstractText>To exploit a cross passive immunotherapy for enterovirus-induced hand-foot-and-mouth disease (HFMD), the cross antiviral activity of a neutralizing antibody against enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) was investigated <i>in vitro</i>. White Leghorn specific-pathogen-free chickens were immunized with EV71 antigens and a specific isolated immunoglobulin (IgY) was prepared from the chicken egg yolk. IgY was further purified and characterized by SDS-PAGE, ELISA, western blotting and bidirectional immune agar diffusion testing. The antiviral activity and dose-response of the IgY were determined by assessing the cytopathic effect in rhabdomyosarcoma (RD) cells <i>in vitro</i>. It was indicated that the levels of IgY were increased at day 7, peaked at week 7 and were maintained at a higher level for 4 weeks following immunization when compared with the negative control. The results of western blotting and bidirectional immune agar diffusion testing revealed that the IgY had cross-binding properties in EV71 and CVA16 strains through targeting the envelope proteins (VP0, VP1 and VP3) of EV71 and CVA16. Neutralization assay results indicated that the infectivity of EV71 and CVA16 strains in RD cells was cross-blocked by IgY in a dose-dependent manner. To conclude, these findings indicate that IgY has cross antiviral activity against EV71 and CVA16 <i>in vitro</i>, and could potentially be developed as a passive immunotherapy for EV71- and CVA16-induced HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Enyi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shuwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of State Key Laboratory of Virology, School of Life Sciences, Wuhan University, Wuhan, Hubei 430000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yonglian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Songqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jingchen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi 541000, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Exp Ther Med</MedlineTA><NlmUniqueID>101531947</NlmUniqueID><ISSNLinking>1792-0981</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgY</Keyword><Keyword MajorTopicYN="N">antiviral activity</Keyword><Keyword MajorTopicYN="N">coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">rhabdomyosarcoma cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31258670</ArticleId><ArticleId IdType="pmc">PMC6566110</ArticleId><ArticleId IdType="doi">10.3892/etm.2019.7529</ArticleId><ArticleId IdType="pii">ETM-0-0-7529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: What's next? Emerg Health Threats J. 2013;6:19780. doi: 10.3402/ehtj.v6i0.19780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SL, Pan H, Liu P, Amer S, Chan TC, Zhan J, Huo X, Liu Y, Teng Z, Wang L, Zhuang H. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. 2015;25:115&#x2013;128. doi: 10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasina M, Domanska A, Palm K, Butcher S. Human picornaviruses associated with neurological diseases and their neutralization by antibodies. J Gen Virol. 2017;98:1145&#x2013;1158. doi: 10.1099/jgv.0.000780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000780</ArticleId><ArticleId IdType="pubmed">28631594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright HT, Jr, Landing BH, Lennette EH, McAllister RM. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med. 1963;268:1041&#x2013;1044. doi: 10.1056/NEJM196305092681904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM196305092681904</ArticleId><ArticleId IdType="pubmed">14001956</ArticleId></ArticleIdList></Reference><Reference><Citation>Legay F, Leveque N, Gacouin A, Tattevin P, Bouet J, Thomas R, Chomelt JJ. Fatal coxsackievirus A-16 pneumonitis in adult. Emerg Infect Dis. 2007;13:1084&#x2013;1086. doi: 10.3201/eid1307.070295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1307.070295</ArticleId><ArticleId IdType="pmc">PMC2878248</ArticleId><ArticleId IdType="pubmed">18214187</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, Torisu H, Hara T. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009;15:1689&#x2013;1691. doi: 10.3201/eid1510.090594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1510.090594</ArticleId><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J. 2004;23:275&#x2013;276. doi: 10.1097/01.inf.0000115950.63906.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000115950.63906.78</ArticleId><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WJ, Arnold JC, Fairchok MP, Danaher PJ, McDonough EA, Blair PJ, Garcia J, Halsey ES, Schofield C, Ottolini M, et al. Epidemiologic, clinical, and virologic characteristics of human rhinovirus infection among otherwise healthy children and adults: Rhinovirus among adults and children. J Clin Virol. 2015;64:74&#x2013;82. doi: 10.1016/j.jcv.2015.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2015.01.007</ArticleId><ArticleId IdType="pmc">PMC4347877</ArticleId><ArticleId IdType="pubmed">25728083</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829&#x2013;837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Poh CL, Fecondo J, Pourianfar H, Shaw J, Grollo L. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. Vaccine. 2012;30:7105&#x2013;7110. doi: 10.1016/j.vaccine.2012.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Wang G, Li XF, Li Y, Zhu SY, Qin CF, Tang R. Alumina-encapsulated vaccine formulation with improved thermostability and immunogenicity. Chem Commun (Camb) 2016;52:6447&#x2013;6450. doi: 10.1039/C6CC02595A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6CC02595A</ArticleId><ArticleId IdType="pubmed">27098047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R, Han J, Deng Y, Yu M, Qin E, Qin C. Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin Infect Dis. 2010;50:125&#x2013;126. doi: 10.1086/649012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/649012</ArticleId><ArticleId IdType="pubmed">20001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669&#x2013;679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8:1775&#x2013;1783. doi: 10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed Z, Cardosa MJ. Status of research and development of vaccines for enterovirus 71. Vaccine. 2016;34:2967&#x2013;2970. doi: 10.1016/j.vaccine.2016.02.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.077</ArticleId><ArticleId IdType="pubmed">26973065</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Bao H, Zhang X, Zhai M, Bao X, Wang D, Zhang S. Epidemiological and genetic analysis concerning the non-enterovirus 71 and non-coxsackievirus A16 causative agents related to hand, foot and mouth disease in Anyang city, Henan Province, China, from 2011 to 2015. J Med Virol. 2017;89:1749&#x2013;1758. doi: 10.1002/jmv.24847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24847</ArticleId><ArticleId IdType="pubmed">28480969</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, et al. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine. 2009;27:3153&#x2013;3158. doi: 10.1016/j.vaccine.2009.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.060</ArticleId><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94. doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1&#x2013;11. doi: 10.1111/j.1365-2249.2005.02834.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2005.02834.x</ArticleId><ArticleId IdType="pmc">PMC1809480</ArticleId><ArticleId IdType="pubmed">16178850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136:111&#x2013;113. doi: 10.1111/j.1365-2249.2004.02412.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02412.x</ArticleId><ArticleId IdType="pmc">PMC1809000</ArticleId><ArticleId IdType="pubmed">15030521</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, Tian X, Jiang T, Qin ED, Qin CF. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J. 2011;8:106. doi: 10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548&#x2013;558. doi: 10.1038/clpt.2008.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2008.170</ArticleId><ArticleId IdType="pubmed">18784655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review. Toxicology. 1995;105:23&#x2013;29. doi: 10.1016/0300-483X(95)03123-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0300-483X(95)03123-W</ArticleId><ArticleId IdType="pubmed">8638282</ArticleId></ArticleIdList></Reference><Reference><Citation>Tini M, Jewell UR, Camenisch G, Chilov D, Gassmann M. Generation and application of chicken egg-yolk antibodies. Comp Biochem Physiol A Mol Integr Physiol. 2002;131:569&#x2013;574. doi: 10.1016/S1095-6433(01)00508-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1095-6433(01)00508-6</ArticleId><ArticleId IdType="pubmed">11867282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Kang HE, Woo HJ. Stability of orally administered immunoglobulin in the gastrointestinal tract. J Immunol Methods. 2012;384:143&#x2013;147. doi: 10.1016/j.jim.2012.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2012.06.001</ArticleId><ArticleId IdType="pubmed">22691618</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson E, St&#xe5;lberg J, Larsson A. IgY stability in eggs stored at room temperature or at + 4&#xb0;C. Br Poult Sci. 2012;53:42&#x2013;46. doi: 10.1080/00071668.2011.646951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00071668.2011.646951</ArticleId><ArticleId IdType="pubmed">22404803</ArticleId></ArticleIdList></Reference><Reference><Citation>Schade R, Staak C, Erhard M, Hugl H, Koch G, Hendriksen C. The production of avian (Egg Yolk) Antibodies: IgY. ATLA. 1997;24:925&#x2013;934.</Citation></Reference><Reference><Citation>Ulmer-Franco AM, Cherian G, Quezada N, Fasenko GM, McMullen LM. Hatching egg and newly hatched chick yolk sac total IgY content at 3 broiler breeder flock ages. Poult Sci. 2012;91:758&#x2013;764. doi: 10.3382/ps.2011-01757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3382/ps.2011-01757</ArticleId><ArticleId IdType="pubmed">22334753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang WW. The use of gene-specific IgY antibodies for drug target discovery. Drug Discov Today. 2003;8:364&#x2013;371. doi: 10.1016/S1359-6446(03)02655-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(03)02655-2</ArticleId><ArticleId IdType="pubmed">12681940</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YH, Park D, Yang G, Lee SH, Bae DK, Kyung J, Kim D, Choi EK, Son JC, Hwang SY, Kim YB. Anti-Helicobacter pylori effects of IgY from egg york of immunized hens. Lab Anim Res. 2012;28:55&#x2013;60. doi: 10.5625/lar.2012.28.1.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.5625/lar.2012.28.1.55</ArticleId><ArticleId IdType="pmc">PMC3315199</ArticleId><ArticleId IdType="pubmed">22474475</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari MR, Ahmadi A, Mirkalantari S, Salimian J. Anti-Vibriocholerae IgY antibody inhibits mortality in suckling mice model. J Natl Med Assoc. 2018;110:84&#x2013;87. doi: 10.1016/j.jnma.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnma.2017.04.001</ArticleId><ArticleId IdType="pubmed">29510849</ArticleId></ArticleIdList></Reference><Reference><Citation>Thu HM, Myat TW, Win MM, Thant KZ, Rahman S, Umeda K, Nguyen SV, Icatlo FC, Jr, Higo-Moriguchi K, Taniguchi K, et al. Chicken Egg Yolk antibodies (IgY) for prophylaxis and treatment of rotavirus diarrhea in human and animal neonates: A concise review. Korean J Food Sci Anim Resour. 2017;37:1&#x2013;9. doi: 10.5851/kosfa.2017.37.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.5851/kosfa.2017.37.1.1</ArticleId><ArticleId IdType="pmc">PMC5355572</ArticleId><ArticleId IdType="pubmed">28316465</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu CY, Huang H, Wang XM, Liu YG, Wang ZG, Cui SJ, Gao HL, Li Z, Li JP, Kong XG. Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens. J Virol Methods. 2006;133:112&#x2013;115. doi: 10.1016/j.jviromet.2005.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2005.10.027</ArticleId><ArticleId IdType="pmc">PMC7112787</ArticleId><ArticleId IdType="pubmed">16325277</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Gao X, Maragh S, Telford WG, Tona A. Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer. Clin Chem. 2009;55:1307&#x2013;1315. doi: 10.1373/clinchem.2008.120576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.120576</ArticleId><ArticleId IdType="pmc">PMC8381244</ArticleId><ArticleId IdType="pubmed">19443566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Cohen B, Hand J, Nokes DJ. A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Method. 1999;78:209&#x2013;217. doi: 10.1016/S0166-0934(98)00178-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-0934(98)00178-5</ArticleId><ArticleId IdType="pubmed">10204711</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, He Y, Lu J. Virus-like particles produced in pichia pastoris induce protective immune responses against coxsackievirus A16 in mice. Med Sci Monit. 2016;22:3370&#x2013;3382. doi: 10.12659/MSM.900380.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.900380</ArticleId><ArticleId IdType="pmc">PMC5036384</ArticleId><ArticleId IdType="pubmed">27659054</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001&#x2013;2007. Ann Acad Med Singapore. 2009;38:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YX, Huang YM, Li QJ, Li XY, Zhou YD, Guo F, Zhou JM, Cen S. A highly conserved amino acid in VP1 regulates maturation of enterovirus 71. PLoS Pathog. 2017;13:e1006625. doi: 10.1371/journal.ppat.1006625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006625</ArticleId><ArticleId IdType="pmc">PMC5634653</ArticleId><ArticleId IdType="pubmed">28938017</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T, King A, Lea S, Newman J, Stuart D. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: The structure of empty capsids of foot-and-mouth disease virus. J Virol. 1997;71:9743&#x2013;9752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen T, Newman J, Guan SH, Tuthill TJ, Belsham GJ. Cleavages at the three junctions within the foot-and-mouth disease virus capsid precursor (P1-2A) by the 3C protease are mutually independent. Virology. 2018;522:260&#x2013;270. doi: 10.1016/j.virol.2018.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2018.07.010</ArticleId><ArticleId IdType="pubmed">30055516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60:797&#x2013;803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Khong WX, Yan B, Premanand B, Alonso S, Chow VT, Kwang J. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One. 2012;7:e29751. doi: 10.1371/journal.pone.0029751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: A review. J Med Food. 2002;5:159&#x2013;169. doi: 10.1089/10966200260398198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10966200260398198</ArticleId><ArticleId IdType="pubmed">12495588</ArticleId></ArticleIdList></Reference><Reference><Citation>Solhi R, Alebouyeh M, Khafri A, Rezaeifard M, Aminian M. In vitro evaluation of cross-strain inhibitory effects of IgY polyclonal antibody against H. pylori. Microb Pathog. 2017;110:682&#x2013;687. doi: 10.1016/j.micpath.2017.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2017.03.025</ArticleId><ArticleId IdType="pubmed">28351713</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller S, Schubert A, Zajac J, Dyck T, Oelkrug C. IgY antibodies in human nutrition for disease prevention. Nutr J. 2015;14:109. doi: 10.1186/s12937-015-0067-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-015-0067-3</ArticleId><ArticleId IdType="pmc">PMC4617726</ArticleId><ArticleId IdType="pubmed">26487372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>